Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Amendment history:
  • Correction (July 1972)

Free access | 10.1172/JCI106467

Cyclic 3′,5′-adenosine monophosphate in human blood platelets: II. Effect of N6-2′-0-dibutyryl cyclic 3′,5′-adenosine monophosphate on platelet function

Edwin W. Salzman and Linda Levine

Department of Surgery, Harvard Medical School, Boston, Massachusetts 02215

Surgical Service, Beth Israel Hospital, Boston, Massachusetts 02215

Find articles by Salzman, E. in: PubMed | Google Scholar

Department of Surgery, Harvard Medical School, Boston, Massachusetts 02215

Surgical Service, Beth Israel Hospital, Boston, Massachusetts 02215

Find articles by Levine, L. in: PubMed | Google Scholar

Published January 1, 1971 - More info

Published in Volume 50, Issue 1 on January 1, 1971
J Clin Invest. 1971;50(1):131–141. https://doi.org/10.1172/JCI106467.
© 1971 The American Society for Clinical Investigation
Published January 1, 1971 - Version history
View PDF
Abstract

The relation of cyclic 3′,5′-adenosine monophosphate to platelet function has been studied by investigating the influence of this compound and of its N6-2′-0-dibutyryl derivative on platelet aggregation and other aspects of platelet behavior after demonstration of adenyl cyclase activity in disrupted platelets.

Dibutyryl cyclic AMP inhibited platelet aggregation induced by ADP, epinephrine, collagen, and thrombin. Cyclic AMP was also inhibitory but was less effective. The platelet “release reaction” was also inhibited; specifically, there was inhibition of the induction of platelet factor 3 activity and of the release of labeled 5-hydroxytryptamine. Platelet swelling produced by ADP was not inhibited.

The action of dibutyryl cyclic AMP did not result from contamination with 5′-AMP, nor was it attributable to production of 5′-AMP by plasma enzymes. Dibutyryl cyclic AMP was degraded to 2′-O-monobutyryl cyclic AMP and to cyclic AMP in plasma, but plasma exhibited no cyclic nucleotide phosphodiesterase activity, and the production of 5′-AMP did not occur. The in vitro effects of dibutyryl cyclic AMP were associated with uptake of the compound by platelets.

Adenyl cyclase activity of platelet homogenates was demonstrated with production of 9.27 × 10-11 (±2.62 × 10-11) mole cyclic AMP per min per 1010 platelets. The activity was increased by NaF and by prostaglandin PGE1 and was decreased by epinephrine. The effect of epinephrine was blocked by phentolamine but not by propanolol. Adenyl cyclase activity was also inhibited by collagen, 5-hydroxytryptamine, and thrombin. ADP, dibutyryl cyclic AMP, and cyclic AMP did not alter adenyl cyclase activity.

These observations are consistent with the hypothesis that platelet aggregation is favored by a decrease in platelet cyclic AMP and inhibited by an increase in cyclic AMP.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 131
page 131
icon of scanned page 132
page 132
icon of scanned page 133
page 133
icon of scanned page 134
page 134
icon of scanned page 135
page 135
icon of scanned page 136
page 136
icon of scanned page 137
page 137
icon of scanned page 138
page 138
icon of scanned page 139
page 139
icon of scanned page 140
page 140
icon of scanned page 141
page 141
Version history
  • Version 1 (January 1, 1971): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts